In vitro multiparameter determination method for the diagnosis and early diagnosis of neurodegenerative disorders
In vitro multiparameter method for the diagnosis and early diagnosis, for determination of the severity and for assessing the course and prognosis of neurodegenerative disorders, in which the concentrations of at least two different vasotropic peptides are determined in a biological fluid from a person suffering from subjective or objectively detectable cognitive impairments, the resulting person-specific measurements are combined computationally to give a person-specific complex reference value, and conclusions are drawn concerning the presence of a neurodegenerative disorder in the person on the basis of the person-specific complex reference value found.
1. A method for the detection and determination of Alzheimer's disease in a patient who is suffering from subjectively or objectively detectable cognitive disturbances potentially associated with Alzheimer's disease, the method comprising:
(a) detecting and quantitating in a plasma or serum sample from the patient at least one vasodilatory peptide selected from the group consisting of atrial natriuretic peptides ANP and adrenomedullin (ADM), wherein the concentration of ANP is determined by measuring the amount of a midregional segment of proANP (MR-proANP) and the concentration of ADM is determined by measuring the amount of a midregional proADM (MR-proADM) fragment consisting of amino acids 45-92 of preproadrenomedullin;
(b) detecting and quantitating in said sample the concentration of a vasoconstrictive peptide, endothelin-1 (ET-1), wherein the concentration of ET-1 peptide in said sample is determined by measuring the amount of a C-terminal proET-1 fragment (CTproET-1) consisting of amino acids 168-212 of pre-proendothelin-1; and
(c) determining a ratio index of the concentration(s) of the one or more vasodilatory peptide(s) to the concentration of the endothelin-1 peptide, wherein a ratio index above the corresponding ratio index determined for healthy controls is indicative of Alzheimer's disease,
wherein at least one of step (a) and step (b) comprises an immunoassay.
2. The method of claim 1 , wherein the ratio index is the ratio index MR-proADM/CT-proET1, wherein the concentrations of MR-proADM and CT-proET1 are determined in pmol/1 and a ratio index of more than 10.0 is indicative for Alzheimer's disease.
3. The method of claim 1 , wherein the ratio index is the ratio index MR-proANP/CT-proET1, wherein the concentrations of MR-proANP and CT-proET1 are determined in pmol/1 and a ratio index of more than 1.15 is indicative for Alzheimer's disease.
4. The method of claim 1 , wherein the ratio index is the ratio index MR-proANP×MR-proADM/CT-proET1, wherein the concentrations of MR-proANP, MR-proADM and CT-proET1 are determined in pmol/1 and a ratio index of more than 0.72 is indicative for Alzheimer's disease.
5. The method of claim 1 , wherein step a) comprises an immunoassay.
6. The method of claim 1 , wherein step b) comprises an immunoassay.
7. The method of claim 1 , wherein both steps a) and b) comprise immunoassays.